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ABSTRACT
Purpose: To determine if models of ovarian clear cell carcinomas (OCCCs) 
harbouring defects in homologous recombination (HR) DNA repair of double strand 
breaks (DSBs) are sensitive to cisplatin and/or PARP inhibition.
Experimental Design: The HR status of 12 OCCC cell lines was determined using 
RAD51/γH2AX foci formation assays. Sensitivity to cisplatin and the PARP inhibitor 
BMN-673 was correlated with HR status. BRCA1, BRCA2, MRE11 and PTEN loss of 
expression was investigated as a potential determinant of BMN-673 sensitivity. A 
tissue microarray containing 50 consecutive primary OCCC was assessed for PTEN 
expression using immunohistochemistry.
Results: A subset of OCCC cells displayed reduced RAD51 foci formation in the 
presence of DNA DSBs, suggestive of HR defects. HR-defective OCCC cells, with the 
exception of KOC-7c, had higher sensitivity to cisplatin/ BMN-673 than HR-competent 
OCCC cell lines (Log10 SF50 –9.4 (SD +/− 0.29) vs –8.1 (SD +/− 0.35), mean 
difference 1.3, p < 0.01). Of the cell lines studied, two, TOV-21G and KOC-7c, showed 
loss of PTEN expression. In primary OCCCs, loss of PTEN expression was observed in 
10% (5/49) of cases.
Conclusions: A subset of OCCC cells are sensitive to PARP inhibition in vitro, 
which can be predicted by HR defects as defined by γH2AX/RAD51 foci formation. 
These results provide a rationale for the testing of HR deficiency and PARP inhibitors 
as a targeted therapy in a subset of OCCCs.
INTRODUCTION
Ovarian clear cell carcinoma (OCCC) is an 
aggressive histological subtype of epithelial ovarian cancer 
(EOC) with a higher rate of de novo resistance to platinum-
based chemotherapy than high-grade serous EOCs [1, 2]. 
OCCCs have been shown to constitute a distinct subtype 
of EOCs histologically and genetically. Unlike high-grade 
serous carcinomas, OCCCs usually lack TP53 mutations 
[3] and germline or somatic BRCA1 or BRCA2 mutations 
[4]. In contrast, OCCCs are characterised by the presence 
of ARID1A mutations [5], activating PIK3CA mutations 
[6], loss of PTEN expression [6, 7], and amplification 
of PPM1D [8]. It should be noted, however, that there is 
evidence to suggest that OCCCs constitute a heterogeneous 
group of cancers at the genetic level, exemplified by the 
existence of subgroups harbouring distinct constellations 
of gene copy number alterations [9] and a varied repertoire 
of somatic mutations [5]. 
Despite the progress in the understanding of the 
molecular basis of OCCCs, patients with this disease 
are still managed with chemotherapy based on platinum 
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salts and taxanes. Given the reported aggressive clinical 
behaviour and generally poor response rates to these 
conventional chemotherapy regimens, patients with 
OCCCs have been shown to have a worse outcome than 
those with other types of EOCs [9, 10]. It should be noted, 
however, that the heterogeneity of OCCCs is also apparent 
in terms of its response to specific therapeutic agents, as 
there are models of OCCCs that have been shown to be 
sensitive to platinum salts [2].
Poly(ADP) ribose polymerase (PARP) inhibitors 
constitute a new class of targeted therapeutic agents that 
have shown great promise in preclinical studies and phase 
I/ II clinical trials based on the principle of synthetic 
lethality [11, 12], PARP inhibitors selectively target cells 
that lack competent homologous recombination (HR) 
DNA repair in the presence of DNA double-strand breaks 
(DSBs) [13]. PARP inhibition leads to an impairment of 
the ability of cells to repair DNA single-strand breaks 
by base excision DNA repair. In cells treated with PARP 
inhibitors, single-strand breaks are not repaired and during 
S-phase, these lead to replication fork stalling and collapse, 
ultimately resulting in DNA DSBs [13]. In normal cells, 
these DSBs are repaired by HR DNA repair. In cancers 
with dysfunctional HR, such as those lacking BRCA1 [14], 
BRCA2 [14], PTEN [15] and RAD51D [16] function, 
PARP inhibitor-induced DSBs cannot be corrected by 
HR, and are repaired by error prone mechanisms (e.g. 
non-homologous end-joining), which result in high levels 
of genetic instability and eventually cell death. Defects 
in HR can be associated with inactivation of multiple 
components of the HR pathway [17, 18]. In particular, 
BRCA1 and BRCA2 loss of function have been shown to 
lead to dysfunctional HR in cancer cells [15, 18] whereas 
the association between PTEN loss of function and 
dysfunctional HR is more controversial [19].   MRE11 loss 
of expression has recently been shown to be associated 
with increased PARP inhibitor sensitivity in prostate, 
colorectal and endometrial cancer cells [20, 21]. 
Consistent with the results from preclinical models 
for the PARP-inhibitor BMN-673 [22, 23], clinical trials 
testing the efficacy of PARP inhibitors, have yielded 
promising results in patients with advanced BRCA1 or 
BRCA2 hereditary breast and ovarian cancers [24–31], but 
also in sporadic high-grade serous EOC [32, 33], which 
often harbour somatic inactivation of genes involved in 
HR DNA repair [34]. Pre-clinical studies [15] and clinical 
evidence from the analysis of a patient with advanced 
endometrial cancer [35] suggests that tumours with loss of 
PTEN expression, a recurrent aberration in OCCC [6, 7], 
may be sensitive to PARP inhibitors. 
Given that OCCCs are heterogeneous at the 
molecular level and that a subgroup of these cancers are 
sensitive to platinum-based chemotherapy, we hypothesised 
that a subset of OCCCs may have dysfunctional HR DNA 
repair of DNA DSBs and that this defect would result 
in sensitivity to platinum salts and PARP inhibitors. To 
address these hypotheses, we analysed a panel of 12 OCCC 
cell lines and a series of 50 primary OCCCs i) to define 
the prevalence of dysfunctional HR DNA repair, ii) to 
determine if subgroups of OCCCs are sensitive to platinum 
salts and/or the PARP inhibitor BMN-673, iii) to determine 
if HR DNA repair defects would be associated with loss 
of PTEN function, and iv) to determine the prevalence of 
PTEN loss of expression in a cohort of primary OCCCs.
RESULTS
A subset of OCCC cells is unable to elicit RAD51 
foci in the presence of DNA DSBs
We sought to determine if OCCC cells would 
harbour defects in HR. The inability of cancer cells to 
elicit RAD51 foci in the presence of DNA DSBs was 
used as a surrogate for dysfunctional HR as previously 
described [14, 15, 41]. We first assessed the ability of 
OCCC cells to elicit RAD51 foci formation in the presence 
of ionising radiation-induced DNA DSBs (Figure 1A–1C). 
As expected, SUM149 and CAPAN1 cells were unable to 
elicit RAD51 foci following exposure to DNA damaging 
agents, given that they harbour deleterious BRCA1 and 
BRCA2 mutations, respectively (Figure 1A and 1B) 
[14, 15, 41]. Although none of the OCCC cells completely 
lacked the ability to elicit RAD51 foci, KOC-7c, TOV-21G, 
KK, RMG-1, and SMOV-2 cells had significantly lower 
proportions of RAD51-positive nuclei in response 
to ionising radiation than HR competent cancer cells 
(i.e. SKBR3 and SUM44, Mann-Whitney U Test, p < 0.01, 
Figure 1A and 1B). These findings suggest that a subset of 
OCCC cells may lack competent HR DNA repair of DSBs. 
A subset of OCCC cells unable to elicit RAD51 
foci in the presence of DSBs harbours PTEN 
gene mutations
As BRCA1, BRCA2, PTEN and MRE11 loss has 
been associated with dysfunctional HR and/or PARP 
inhibitor sensitivity, we assessed the expression of 
BRCA1, BRCA2, PTEN and MRE11 in 12 OCCC cell 
lines included in this study by western blotting. All 
OCCC cells expressed similar levels of BRCA1, BRCA2 
and MRE11 protein (Figure 1D). In addition, all OCCC 
cells with competent HR as defined by the RAD51 foci 
formation assay expressed PTEN protein. Out of the five 
cell lines with reduced RAD51 foci in the presence of 
DSBs, however, two, TOV-21G and KOC-7c, showed 
loss of PTEN expression (Figure 1D) and harboured PTEN 
frameshift mutations (TOV-21G, c.795_795delA; KOC-7c, 
c.968_968delA; Figure 1E). None of the cell lines tested 
displayed PTEN homozygous deletions and both PTEN-
null cell lines (TOV-21G and KOC-7c) harboured two 
copies of the PTEN locus as defined by FISH (data not 
shown). No BRCA1 was detected in these cell lines 
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Figure 1: A subset of OCCC cells is unable to elicit RAD51 foci in the presence of DNA DSBs. A panel of 12 OCCC 
cell lines were subjected to RAD51 foci formation assays to determine their homologous recombination (HR) function in the presence 
of DNA double strand breaks (DSBs). Cell lines were treated with ionising radiation before immunofluorescent detection of γH2AX 
foci (markers of DNA DSBs) and RAD51 foci (markers of competent HR) was undertaken (A). Akin to CAPAN1 (BRCA2-mutant) and 
SUM149 (BRCA1-mutant) control cells, five OCCC cell lines showed reduced RAD51 foci formation (i.e. TOV-21G, KOC-7c, SMOV-2, 
RMG-1, and KK) (B). The remaining seven OCCC cell lines displayed RAD51 foci formation at similar levels to HR-competent SKBR3 
and SUM44 cells (B). All cell lines showed similar levels of γH2AX foci formation (C). Western blot analysis of PTEN, MRE11, BRCA1 
and BRCA2 in 12 OCCC cell lines. Beta-tubulin was employed as loading control. Two cell lines (TOV-21G and KOC-7c) showed loss of 
PTEN expression (D). PTEN Sanger sequencing traces of TOV-21G (top) and KOC-7c (bottom), which both harboured a PTEN frameshift 
mutation (c.795het_delA in TOV-21G and c.968het_delA in KOC-7c), red arrows, (E). The top sequencing trace in each panel represents 
the wild type sequence, while the cell line sequence showing the mutation is shown below it. In all panels, cell lines with reduced RAD51 
foci formation (HR defective) are marked in red, those with normal RAD51 foci formation (HR competent) are marked in black, those with 
BRCA1 or BRCA2 loss of function are marked in blue, and those previously documented to be HR competent in purple.
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(Supplementary Table S3). Taken together, these data 
suggest that a subset of OCCC cell lines harbour defects 
in HR, some of which are associated with loss of PTEN 
expression. Consistent with these data, when a cohort of 50 
primary OCCC tumour samples were assessed for PTEN 
loss of expression by immunohistochemistry (Figure 2), 
5/49 analysable cases were found to harbour PTEN loss 
(10%, Supplementary Table S1). This is less frequent than 
previously reported for OCCCs (27.5–37.5%) [7, 43].
Sensitivity of OCCC cell lines to cisplatin and 
BMN-673 is associated with HR functional status 
Given that a subset of OCCC cells was unable to 
elicit RAD51 foci in the presence of DNA DSBs, we 
sought to define whether these cell lines would show a 
higher sensitivity to cisplatin and PARP inhibitors than the 
remaining OCCCs. Interestingly, cell lines with low levels of 
RAD51 foci formation upon treatment with ionising radiation 
were sensitive to cisplatin and BMN-673 (Figure 3A and 3B), 
with survival fractions 50 (SF50s) similar to those of the 
BRCA2-mutant CAPAN1 cells, with the exception of KOC-7c. 
On the other hand, OCCC cells able to elicit RAD51 foci 
upon treatment with ionising radiation were relatively 
resistant to cisplatin and BMN-673 (Figure 3A and 3B).
Given that KOC-7c cells elicited relatively low 
numbers of RAD51 foci upon treatment with ionising 
radiation, but displayed a relative resistance to cisplatin 
and BMN-673 (Figure 3A and 3B), we sought to define the 
ability of these cells to elicit RAD51 and γH2AX foci upon 
treatment with these agents. Upon treatment with cisplatin 
and BMN-673, KOC-7c, TOV-21G, KK, RMG-1, and 
SMOV-2 cells displayed significantly lower proportions 
of RAD51-positive nuclei than the remaining OCCC 
cells (7.1 (SD +/− 1.37) vs 18.8 (SD +/− 3.31), p < 0.05) 
(Figure 3C). Importantly, however, the assessment of 
γH2AX foci formation upon treatment with cisplatin 
or BMN-673 in these cells revealed a lower proportion 
of γH2AX-positive nuclei in KOC-7c cells than in the 
remaining OCCC cell lines (17.2  vs 43.9 (SD +/− 7.68), 
p < 0.05) (Figure 3D). These observations provide strong 
circumstantial evidence that cisplatin and BMN-673 are 
not causing DNA damage in KOC-7c cells. 
DISCUSSION
OCCCs have been shown to constitute a 
heterogeneous group of tumours in terms of their 
genetic features [9] and response to therapy [44]. Here 
we demonstrate that OCCCs are also heterogeneous in 
regards to their ability to elicit competent HR DNA repair. 
A subset of OCCC cells exhibited impaired HR DNA 
repair of DSBs, as determined by RAD51 foci formation 
assays, and were shown to be sensitive to cisplatin and 
BMN-673. In addition, our results also provided evidence 
to suggest that PTEN loss of function may be associated 
with impaired HR DNA repair in a subset of OCCC cells 
and was found to be lost in 10% of primary OCCCs. 
The role of PTEN loss of function in HR DNA 
repair of DSBs is controversial. Studies have failed to 
demonstrated a significant association between PTEN 
loss of function [45, 46] and either sensitivity to PARP 
inhibitors or HR defects have not yet provided a definite 
mechanism for this association [15, 47]. Possible 
mechanisms include the role of PTEN as a modulator 
of RAD51 transcription [48]. Importantly, the impact of 
PTEN loss of function in HR DNA repair of DSBs may be 
context dependent. While in endometrial cancer [15, 35] 
Figure 2: PTEN expression in primary OCCCs. Using a validated antibody to PTEN, and previously reported scoring systems, 
PTEN expression was assessed in a panel of 50 primary OCCCs in a previously constructed tissue microarray. Cases were reviewed by at 
least two pathologists and discordant scores reassessed on whole tissue sections. Complete loss of PTEN expression was identified in 5/49 
analysable cases (10%).  Representative haematoxylin & eosin micrographs (left) and PTEN immunohistochemistry (right) of a PTEN-
negative (top) and a PTEN-positive OCCC. 
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and gliomas [47] PTEN loss of function results in impaired 
HR DNA repair and sensitivity to PARP inhibitors, similar 
effects have not been observed in non-small cell lung 
cancer and prostate cancer [20, 49]. Endocrine factors, 
in particular estrogen levels may also play a role, in 
sensitizing PTEN-null endometrial cancer cells to PARP 
inhibitors [50]. It is also plausible that the chronology of 
the loss of PTEN function may determine its impact on HR 
DNA repair. In endometrial cancers, loss of PTEN is an 
early event, whereas in prostate cancer, there is evidence 
Figure 3: Sensitivity of OCCC cell lines to cisplatin and BMN-673 can be predicted by HR functional status and PTEN 
status. Given the recognised sensitivity of cells with defects in HR to agents that cause DNA double strand breaks, the panel of 12 OCCC 
cell lines were subjected to treatment with cisplatin or the PARP inhibitor BMN-673. With the exception of KOC-7c, all HR defective cell 
lines showed dose-response curves to cisplatin (A) and BMN-673 (B) with sensitive profiles, while all HR competent cell lines (with the 
exception of OVTOKO) showed dose-response curves with resistant profiles. CAPAN1 cells were used as controls for this experiment. 
When outliers were excluded (KOC-7c, circled in scatter plots, A and B as well as OVSAYO circled in scatter plot B), HR defective cell 
lines had cisplatin and BMN-673 SF50 concentrations that were significantly lower than those of HR competent cell lines (Mann-Whitney 
U test, p < 0.01) Assessment of RAD51 (C) and γH2AX (D) foci following treatment with cisplatin and BMN-673 demonstrated that HR 
defective cell lines had a lower rate of RAD51 foci formation compared to HR competent cells (C). KOC-7c, did not form γH2AX to the 
same degree as other treated cells (D), suggesting cisplatin and BMN-673 may be subject to drug efflux. In all panels, HR defective cell lines 
are marked in red, HR competent cell lines are marked in black, those with BRCA1/2 mutations are marked in blue, and those previously 
documented to be HR competent in purple. Scatter plots in A and B are annotated with the mean and standard error of mean (SEM).
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to suggest that PTEN loss is a late event [19]. More recent 
data in prostate cancer suggest that the effects of PTEN 
loss on cell growth and response to PARP inhibition are 
context dependent [51]; in a series of in vitro and in vivo 
experiments using pten heterozygous, pten null, with or 
without tp53 loss, mouse embryonic fibroblasts (MEFs) or 
mice, it was demonstrated that in a p53 proficient setting, 
treatment of PTEN–deficient cells with PARP inhibitors 
leads to a senescence response. By comparison, upon loss 
of p53, the response is more apoptotic. Furthermore, the 
group demonstrated that treatment with PARP inhibitor 
leads to AKT activation through the PI3K cascade, which 
can be mitigated with combination therapy with dual PI3K 
inhibitors and PARP inhibitors.
Our results are consistent with those of previous 
reports suggesting that PTEN loss of function is associated 
with defective HR-mediated repair of DNA DSBs, as 
defined by RAD51 foci formation [15, 18]. Both OCCC 
cell lines studied here that harbour PTEN loss of function 
(TOV-21G and KOC-7c) exhibit impaired HR DNA repair 
as determined by RAD51 foci formation. In the light of 
the recent data in prostate cancer discussed above, it is 
possible that these two events (PTEN loss of function and 
impaired HR DNA repair) may not be causally linked in 
isolation; PTEN loss of function may be a bystander event 
in these HR defective OCCC cell lines, or a hitherto as 
yet undiscovered epistatic interaction may be required 
for PTEN loss of function to be mechanistically linked 
to impaired HR DNA repair. Further functional studies 
assessing PTEN loss of function in OCCC are required to 
clarify this issue. Given that aberrations in several other 
genes in the HR pathway can lead to defects in HR [18], it 
is plausible that other HR DNA repair-related genes may 
be lost in a subgroup of OCCCs [24, 25, 52]. Through a 
reanalysis of the results by Tan et al. [9], we have ruled 
out EMSY amplification [41] as a potential cause of HR 
deficiency in these cells, as none of them harboured this 
genetic aberration (data not shown). Further studies to 
define the basis of the deficient HR DNA repair in these 
cells are warranted.
Contrary to the observations derived from the 
experiments performed with BMN-673, where all BMN-
673-sensitive cell lines were HR DNA deficient, OVTOKO 
cells exhibited an exquisite sensitivity to cisplatin, despite 
being HR competent. The fact that OVTOKO was resistant 
to BMN-673 suggests this cisplatin sensitivity is not 
mediated by a defect in HR, and that impaired HR-mediated 
repair of DNA DSBs is not the only determinant of cisplatin 
sensitivity [53, 54].
This study has several limitations. Although the 
OCCC models tested in this study have been shown to 
recapitulate the genetic and transcriptomic features of 
primary OCCCs [8, 9], seven of the 12 cell lines assessed in 
this study had cisplatin SF50s comparable to those CAPAN1 
(sub-micromolar concentrations). Hence, there might be 
an enrichment for chemotherapy–sensitive OCCCs in this 
panel of cell lines. 
In conclusion, we have identified a subset of OCCC 
cell lines that harbour defects in HR-mediated repair of 
DNA DSBs. This preclinical study provides a rationale 
for the assessment of HR deficiency in vivo to potentially 
identify a role of PARP inhibitors in this histological subset.
MATERIALS AND METHODS
Further details of all the methods described here are 
found in the Supplementary Methods.
RAD51 and γH2AX foci assessment
To determine if cancer cells would have 
dysfunctional HR repair of DNA DSBs, Nuclear γ-H2AX 
and RAD51 foci formation was employed as previously 
described [15]. Details of the methods used are described 
in the Supplementary Methods. To determine HR status, 
RAD51 foci formation in response to 10 Gy of ionizing 
radiation was assessed. The differential response of 
HR competent and HR defective cells to either 10 μM 
cisplatin for 6 hrs or 10 μM BMN-673 for 12 hrs was 
then determined. 
Immunoblotting
Western blotting was performed as previously 
described [36], using anti-β-tubulin (ab6046, Abcam, 
Cambridge, UK), anti-PTEN (138G6, Cell Signaling 
Technology, Danvers, MA, USA), anti-BRCA2 (Ab-1 
[OP95], Calbiochem/Merck, Nottingham, UK) and anti-
BRCA1 (C-20, Santa Cruz Biotechnology) antibodies.
Sanger sequencing
Sequencing of the full-length cDNA of PTEN was 
performed for all cell lines as previously described [8]. 
Mutations were confirmed by a repeat PCR from a new 
cDNA from the cell line harbouring the mutation and by 
sequencing of forward and reverse strands.
Assessment of PTEN copy number in OCCC cells
To determine PTEN copy number in OCCC cells 
and if any OCCC cells harboured homozygous deletions 
of PTEN, fluorescence in situ hybridisation (FISH) was 
performed as previously described [9, 15]. The Vysis 
PTEN/CEP10 dual colour FISH probe (Abbott Molecular, 
Des Plaines, IL, USA) was hybridised to slides as 
previously described [37]. 
Cisplatin sensitivity assays
Cisplatin sensitivity assays were carried out in 
96 well plates, in triplicate, as previously described 
[15]. OCCC cells were grown for at least seven days, 
using CAPAN1 as a HR DNA repair-deficient and 
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cisplatin- sensitive control [38–40]. Cells were treated 
with DMSO (control) or cisplatin (serial dilutions; 10–7M 
to 10–4M) (Sigma Aldrich). CellTiter Glo Luminescent 
Cell Viability Assay (Promega, UK) was used according 
to manufacturer’s instructions to determine the survival 
fraction of cisplatin vs DMSO-treated cells.
BMN-673 sensitivity assays
BMN-673 sensitivity was determined using colony 
formation assays (CFAs) in six well plates in triplicate, as 
previously described [15]. Cells were treated with 10–7M 
to 10–11M BMN-673 every 2 days. After 14 days cells were 
fixed and cell number quantified with a sulphorhodamine 
B assay, as previously described [15, 41].
Patient samples and tumour characteristics
Formalin-fixed paraffin-embedded (FFPE) samples 
from 50 consecutive primary OCCCs were retrieved from 
the pathology files of The Royal Marsden Hospital, London, 
The Edinburgh Royal Infirmary, The Royal Hospital Group, 
Belfast and The Hammersmith Hospital, London, as 
previously described [8]. Patient demographics and tumour 
characteristics are summarised in Supplementary Table S1, 
in line with REMARK guidelines (Supplementary 
Table S2). Samples were anonymised prior to analysis 
and the study approved by local ethical committees of the 
authors’ institutions. All cases were reviewed and diagnosis 
of clear cell carcinoma confirmed as previously described 
[8]. Tissue microarrays (TMAs) were constructed from 
paraffin blocks with triplicate 0.6 mm tumour cores, 
containing 50 samples and normal tissue controls, as 
previously described [9]. Surgical and adjuvant therapy 
are described in Supplementary Table S1.
Immunohistochemistry (IHC)
Representative 3 µm-thick sections of the TMA 
described above were subjected to immunohistochemistry 
(IHC) using an antibody against PTEN  (6H2.1  Dilution 
1:100, Antigen retrieval, Dako target retrieval solution, 
pH9, 20 min 97C° DAKO, Glostrup, Denmark). The 
protocol for PTEN immunohistochemical analysis was 
previously validated [15]. Immunohistochemical analysis 
was interpreted by at least two pathologists (AC-F, AG 
and/ or JRF) using a semi-quantitative scoring system. 
Nuclear and cytoplasmic PTEN expression was scored 
using the Quick Score method [42], with cases defined as 
PTEN negative if nuclear expression was absent (i.e. Quick 
Score = 0). Cases with discordant scores between replicate 
cores, or those with missing cores from the TMA were 
assessed on full sections by the three pathologists on a 
multi-headed microscope and a consensus score for each 
was rendered. 
Statistical analysis
All statistical analyses were carried out in Prism 
6.05 (Graphpad Software Inc., California, USA). Details 
of statistical analyses are described in the Supplementary 
Methods. A two-tailed p value < 0.05 was considered 
significant.
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